Christopher Cabell
Known title: President & Head of R&DCIK: 0001814928
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Zura Bio Named Top Pick by Guggenheim Amid Recent Price Gains. Zura Bio was highlighted as a top pick by Guggenheim, contributing to its recent upward movement alongside other stocks. The company's share price has risen, though it remains well below the average analyst target of $18.00. Current trading levels sit near the lower end of its 52-week range, reflecting a significant gap between current market price and long-term valuation estimates.
Transaction History
| IKT | ▼ Sell | Other | 338,282 | $0 | 2/21/2026 | View on chart |
| ZURA | ▲ Buy | Grant | 162,060 | $0 | 5/18/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Inhibikase Announces Nasdaq Inducement Grants
Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.
Inhibikase Announces Nasdaq Inducement Grants. Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.